Skip Nav Destination
Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia
The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19
Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study
Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children
Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML
Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features
Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature
Association of ABO blood group with bleeding severity in patients with bleeding of unknown cause
Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide
Issue Archive
Table of Contents
STIMULUS REPORT
Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia
Clinical Trials & Observations
Jorge J. Castillo,Edward N. Libby,Stephen M. Ansell,M. Lia Palomba,Kirsten Meid,Catherine A. Flynn,Carly Leventoff,Christopher B. Hergott,Tomasz Sewastianik,Elizabeth A. Morgan,Ruben Carrasco,Jonathan R. Fromm,Guang Yang,Zachary Hunter,Steven P. Treon
SYSTEMATIC REVIEWS
CLINICAL TRIALS AND OBSERVATIONS
The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19
Clinical Trials & Observations
Ryan L. Hoiland,Nicholas A. Fergusson,Anish R. Mitra,Donald E. G. Griesdale,Dana V. Devine,Sophie Stukas,Jennifer Cooper,Sonny Thiara,Denise Foster,Luke Y. C. Chen,Agnes Y. Y. Lee,Edward M. Conway,Cheryl L. Wellington,Mypinder S. Sekhon
Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response
Clinical Trials & Observations
Ok-kyong Chaekal,Andromachi Scaradavou,Emeline Masson Frenet,Maria S. Albano,Melissa Cushing,Pinkal Desai,Ludy Dobrila,Usama Gergis,Danielle Guarneri,Jing-Mei Hsu,Sangmin Lee,Sebastian A. Mayer,Adrienne A. Phillips,Nina Orfali,Ellen K. Ritchie,Gail J. Roboz,Cynthia Romeo,Michael S. Samuel,Tsiporah Shore,Koen van Besien
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase
Clinical Trials & Observations
John O. Mascarenhas,Raajit K. Rampal,Heidi E. Kosiorek,Rupali Bhave,Elizabeth Hexner,Eunice S. Wang,Aaron Gerds,Camille N. Abboud,Marina Kremyanskaya,Dimitry Berenzon,Olatoyosi Odenike,Noushin Farnoud,Aishwarya Krishnan,Rona Singer Weinberg,Erin McGovern,Mohamed E. Salama,Vesna Najfeld,Juan S. Medina-Martinez,Juan E. Arango Ossa,Max F. Levine,Yangyu Zhou,Lonette Sandy,Mark L. Heaney,Ross L. Levine,Ruben A. Mesa,Amylou C. Dueck,Ronald Hoffman
HEMATOPOIESIS AND STEM CELLS
IMMUNOBIOLOGY AND IMMUNOTHERAPY
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
Clinical Trials & Observations
Jayakumar Vadakekolathu,Catherine Lai,Stephen Reeder,Sarah E. Church,Tressa Hood,Anbarasu Lourdusamy,Michael P. Rettig,Ibrahim Aldoss,Anjali S. Advani,John Godwin,Matthew J. Wieduwilt,Martha Arellano,John Muth,Tung On Yau,Farhad Ravandi,Kendra Sweet,Heidi Altmann,Gemma A. Foulds,Friedrich Stölzel,Jan Moritz Middeke,Marilena Ciciarello,Antonio Curti,Peter J. M. Valk,Bob Löwenberg,Ivana Gojo,Martin Bornhäuser,John F. DiPersio,Jan K. Davidson-Moncada,Sergio Rutella
Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study
Clinical Trials & Observations
Kentaro Yonekura,Shigeru Kusumoto,Ilseung Choi,Nobuaki Nakano,Asahi Ito,Youko Suehiro,Yoshitaka Imaizumi,Makoto Yoshimitsu,Kisato Nosaka,Eiichi Ohtsuka,Michihiro Hidaka,Tatsuro Jo,Hidenori Sasaki,Yukiyoshi Moriuchi,Masao Ogata,Hiro Tatetsu,Kenji Ishitsuka,Yasushi Miyazaki,Ryuzo Ueda,Atae Utsunomiya,Takashi Ishida
Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children
Clinical Trials & Observations
Caroline Diorio,Pamela A. Shaw,Edward Pequignot,Alena Orlenko,Fang Chen,Richard Aplenc,David M. Barrett,Hamid Bassiri,Edward Behrens,Amanda M. DiNofia,Vanessa Gonzalez,Natalka Koterba,Bruce L. Levine,Shannon L. Maude,Nuala J. Meyer,Jason H. Moore,Michele Paessler,David L. Porter,Jenny L. Bush,Don L. Siegel,Megan M. Davis,Donglan Zhang,Carl H. June,Stephan A. Grupp,J. Joseph Melenhorst,Simon F. Lacey,Scott L. Weiss,David T. Teachey
Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64–labeled daratumumab
Amrita Krishnan,Vikram Adhikarla,Erasmus K. Poku,Joycelynne Palmer,Ammar Chaudhry,Van Eric Biglang-awa,Nicole Bowles,Nitya Nathwani,Michael Rosenzweig,Firoozeh Sahebi,Chatchada Karanes,Jennifer Simpson,James F. Sanchez,Dave Yamauchi,Maria Parayno,Arnab Chowdhury,Enrico Caserta,Guido Marcucci,Russell Rockne,Anna M. Wu,Jeffrey Wong,Stephen J. Forman,David Colcher,Paul Yazaki,John Shively,Flavia Pichiorri
ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells
Florent Amatore,Nicolas Ortonne,Marc Lopez,Florence Orlanducci,Rémy Castellano,Saskia Ingen-Housz-Oro,Amandine De Croos,Clémentine Salvado,Laurent Gorvel,Armelle Goubard,Yves Collette,Réda Bouabdallah,Jean-Marc Schiano,Nathalie Bonnet,Jean-Jacques Grob,Philippe Gaulard,Martine Bagot,Armand Bensussan,Philippe Berbis,Daniel Olive
LYMPHOID NEOPLASIA
Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia
Hiroo Ueno,Kenichi Yoshida,Yusuke Shiozawa,Yasuhito Nannya,Yuka Iijima-Yamashita,Nobutaka Kiyokawa,Yuichi Shiraishi,Kenichi Chiba,Hiroko Tanaka,Tomoya Isobe,Masafumi Seki,Shunsuke Kimura,Hideki Makishima,Masahiro M. Nakagawa,Nobuyuki Kakiuchi,Keisuke Kataoka,Tetsuichi Yoshizato,Dai Nishijima,Takao Deguchi,Kentaro Ohki,Atsushi Sato,Hiroyuki Takahashi,Yoshiko Hashii,Sadao Tokimasa,Junichi Hara,Yoshiyuki Kosaka,Koji Kato,Takeshi Inukai,Junko Takita,Toshihiko Imamura,Satoru Miyano,Atsushi Manabe,Keizo Horibe,Seishi Ogawa,Masashi Sanada
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes
Hanna Scholze,Regan E. Stephenson,Raymond Reynolds,Shivem Shah,Rishi Puri,Scott D. Butler,Vicenta Trujillo-Alonso,Matthew R. Teater,Herman van Besien,Destini Gibbs-Curtis,Hideki Ueno,Salma Parvin,Anthony Letai,Susan Mathew,Ankur Singh,Ethel Cesarman,Ari Melnick,Lisa Giulino-Roth
MYELOID NEOPLASIA
Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML
Clinical Trials & Observations
Giuseppe Visani,Federica Loscocco,Mike Dennis,Eliana Zuffa,Anna Candoni,Alberto Sensi,Barbara Giannini,Gerardo Musuraca,Anna Maria Mianulli,Marino Clavio,Marco Rocchi,Davide Gibellini,Mohsen Navari,Amanda Gilkes,Pier Paolo Piccaluga,Alessandro Isidori
Morphologic remission status is limited compared to ΔN flow cytometry: a Children’s Oncology Group AAML0531 report
Lisa Eidenschink Brodersen,Robert B. Gerbing,M. Laura Pardo,Todd A. Alonzo,Dana Paine,Wayne Fritschle,Fan-Chi Hsu,Jessica A. Pollard,Richard Aplenc,Samir B. Kahwash,Betsy Hirsch,Susana Ramondi,Denise Wells,E. Anders Kolb,Alan S. Gamis,Soheil Meshinchi,Michael R. Loken
Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models
Emma Morrish,Anthony Copeland,Donia M. Moujalled,Jason A. Powell,Natasha Silke,Ann Lin,Kate E. Jarman,Jarrod J. Sandow,Gregor Ebert,Liana Mackiewicz,Jessica A. Beach,Elizabeth L. Christie,Alexander C. Lewis,Giovanna Pomilio,Karla C. Fischer,Laura MacPherson,David D. L. Bowtell,Andrew I. Webb,Marc Pellegrini,Mark A. Dawson,Stuart M. Pitson,Andrew H. Wei,John Silke,Gabriela Brumatti
Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38+ stem and progenitor cells in AML and CML
Harald Herrmann,Irina Sadovnik,Gregor Eisenwort,Thomas Rülicke,Katharina Blatt,Susanne Herndlhofer,Michael Willmann,Gabriele Stefanzl,Sigrid Baumgartner,Georg Greiner,Axel Schulenburg,Niklas Mueller,Werner Rabitsch,Martin Bilban,Gregor Hoermann,Berthold Streubel,Daniel A. Vallera,Wolfgang R. Sperr,Peter Valent
Acute myeloid leukemia–induced remodeling of the human bone marrow niche predicts clinical outcome
Yiyang Chen,Lina Marie Hoffmeister,Yasmin Zaun,Lucas Arnold,Kurt Werner Schmid,Bernd Giebel,Ludger Klein-Hitpass,Helmut Hanenberg,Anthony Squire,H. Christian Reinhardt,Ulrich Dührsen,Stefanie Bertram,Maher Hanoun
Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features
Clinical Trials & Observations
Xavier Calvo,Nieves Garcia-Gisbert,Ivonne Parraga,Joan Gibert,Lourdes Florensa,Marcio Andrade-Campos,Brayan Merchan,Sara Garcia-Avila,Sara Montesdeoca,Concepción Fernández-Rodríguez,Marta Salido,Anna Puiggros,Blanca Espinet,Luís Colomo,David Roman-Bravo,Beatriz Bellosillo,Ana Ferrer,Leonor Arenillas
Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature
Clinical Trials & Observations
Ali Nehme,Hassan Dakik,Frédéric Picou,Meyling Cheok,Claude Preudhomme,Hervé Dombret,Juliette Lambert,Emmanuel Gyan,Arnaud Pigneux,Christian Récher,Marie C. Béné,Fabrice Gouilleux,Kazem Zibara,Olivier Herault,Frédéric Mazurier
THROMBOSIS AND HEMOSTASIS
Bleeding severity in patients with rare bleeding disorders: real-life data from the RBiN study
Joline L. Saes,for the RBiN Study Group,Marieke J. A. Verhagen,for the RBiN Study Group,Karina Meijer,for the RBiN Study Group,Marjon H. Cnossen,for the RBiN Study Group,Roger E. G. Schutgens,for the RBiN Study Group,Marjolein Peters,for the RBiN Study Group,Laurens Nieuwenhuizen,for the RBiN Study Group,Felix J. M. van der Meer,for the RBiN Study Group,Ilmar C. Kruis,for the RBiN Study Group,Waander L. van Heerde,for the RBiN Study Group,Saskia E. M. Schols,for the RBiN Study Group
Association of ABO blood group with bleeding severity in patients with bleeding of unknown cause
Clinical Trials & Observations
Dino Mehic,Stefanie Hofer,Christof Jungbauer,Alexandra Kaider,Helmuth Haslacher,Ernst Eigenbauer,Judit Rejtő,Dieter Schwartz,Bernd Jilma,Cihan Ay,Ingrid Pabinger,Johanna Gebhart
TRANSFUSION MEDICINE
TRANSPLANTATION
Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide
Clinical Trials & Observations
Jonathan A. Webster,Leo Luznik,Hua-Ling Tsai,Philip H. Imus,Amy E. DeZern,Keith W. Pratz,Mark J. Levis,Ivana Gojo,Margaret M. Showel,Gabrielle Prince,Javier Bolaños-Meade,Lukasz P. Gondek,Gabriel Ghiaur,W. Brian Dalton,Tania Jain,Ephraim J. Fuchs,Douglas E. Gladstone,Christian B. Gocke,Syed Abbas Ali,Carol Ann Huff,Ivan M. Borrello,Lode Swinnen,Nina Wagner-Johnston,Richard F. Ambinder,Richard J. Jones,B. Douglas Smith
-
Cover Image
Cover Image
COVER FIGURE
Blood cells flowing through a vein. Credit: ID 55652670 © Cornelius20| Dreamstime.com. - PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Advertisement intended for health care professionals